Jun

    REMS Litigation-Key Insights From Government and Private Practitioners

    11 AM EDT

    Background: Brand name drug companies are increasingly invoking their Risk Evaluation and Mitigation Strategies (REMS) to deny potential generic competitors access to their products.  Specifically, branded drug companies have used REMS to deny prospective generic pharmaceutical companies access to critical drug samples.  While the FTC has yet to file enforcement actions for invoking REMS to preclude or delay generic competition, it has announced that REMS misuse is an enforcement priority and has filed an amicus brief in private antitrust litigation. Third Circuit courts have also recently weighed in on the issue.  This panel will review those decisions, along with the background of REMS generally, to shed light on some important lessons for antitrust lawyers.

    FREE:  Antitrust Section Members, Government, Non-profit Employees, Students
    $25 Other Non-Members

    Explore Section benefits or call 1-800-285-2221 to join. Code RAT14IP25.   For this and all upcoming events visit http://ambar.org/atevents.
     
    CLE
    The ABA is not seeking CLE credit for this program.

    Audio Archive
    Provided all releases are obtained, MP3 recordings of this program will be available to Section members on the Committee Program Audio page.

     

    $25
    NON-MEMBERS
    $10
    MEMBERS
    $0
    SECTION MEMBERS
    Register Now *Additional discounts may apply at checkout

    Log In to view your rate

    REMS Litigation-Key Insights From Government and Private Practitioners

    Event Details

    Format

    Teleconference

    Date

    Jun 16, 2016

    2016-06-16T11:00:00-04:00 2016-06-16T12:00:00-04:00 REMS Litigation-Key Insights From Government and Private Practitioners

    Background: Brand name drug companies are increasingly invoking their Risk Evaluation and Mitigation Strategies (REMS) to deny potential generic competitors access to their products.  Specifically, branded drug companies have used REMS to deny prospective generic pharmaceutical companies access to critical drug samples.  While the FTC has yet to file enforcement actions for invoking REMS to preclude or delay generic competition, it has announced that REMS misuse is an enforcement priority and has filed an amicus brief in private antitrust litigation. Third Circuit courts have also recently weighed in on the issue.  This panel will review those decisions, along with the background of REMS generally, to shed light on some important lessons for antitrust lawyers.

    FREE:  Antitrust Section Members, Government, Non-profit Employees, Students
    $25 Other Non-Members

    Explore Section benefits or call 1-800-285-2221 to join. Code RAT14IP25.   For this and all upcoming events visit http://ambar.org/atevents.
     
    CLE
    The ABA is not seeking CLE credit for this program.

    Audio Archive
    Provided all releases are obtained, MP3 recordings of this program will be available to Section members on the Committee Program Audio page.

     

    Speakers

    Elinor Hoffmann

    Office of the Attorney General

    Mark Ford

    WilmerHale

    Robert Davis

    Venable LLP

    Sponsors

    Health Care and Pharmaceuticals Committee

    Section of Antitrust Law

    Moderators

    Related Products

    Related On-Demand CLE